​

Monopar Therapeutics (MNPR) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MNPR Stock Forecast

Monopar Therapeutics (MNPR) stock forecast, based on 14 Wall Street analysts, predicts a 12-month average price target of $126.00, with a high of $145.00 and a low of $105.00. This represents a 12.12% increase from the last price of $112.38.

- $30 $60 $90 $120 $150 High: $145 Avg: $126 Low: $105 Last Closed Price: $112.38

MNPR Stock Rating

Monopar Therapeutics stock's rating consensus is Buy, based on 14 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 11 Buy (78.57%), 3 Hold (21.43%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 14 0 3 11 Strong Sell Sell Hold Buy Strong Buy

MNPR Price Target Upside V Benchmarks

TypeNameUpside
StockMonopar Therapeutics12.12%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts2919
Avg Price Target$137.50$125.22$117.95
Last Closing Price$112.38$112.38$112.38
Upside/Downside22.35%11.43%4.96%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 26481--13
Aug, 2649---13
Jul, 2649---13
Jun, 2649---13
May, 26410---14
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 11, 2026Barclays$145.00$109.9631.87%29.03%
Aug 17, 2026Maxwell SkorMorgan Stanley$130.00$116.1811.90%15.68%
Aug 13, 2026Barclays$128.00$114.9011.40%13.90%
Aug 13, 2026Kristen KluskaCantor Fitzgerald$119.00$114.903.57%5.89%
Aug 12, 2026Jeet MukherjeeBTIG$133.00$114.9015.75%18.35%
Jul 23, 2026UBS$125.00$112.4811.13%11.23%
Jul 22, 2026H.C. Wainwright$125.00$112.6310.98%11.23%
Jun 30, 2026BTIG$117.00$94.5623.73%4.11%
Jun 29, 2026UBS$105.00$87.6819.75%-6.57%
Jun 02, 2026Piper Sandler$105.00$64.4063.04%-6.57%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 11, 2026BarclaysOverweightOverweighthold
Aug 17, 2026Morgan StanleyOverweightOverweighthold
Aug 13, 2026BarclaysOverweightOverweighthold
Aug 13, 2026Cantor FitzgeraldOverweightNeutraldowngrade
Aug 12, 2026BTIGBuyBuyhold
Jul 23, 2026H.C. WainwrightBuyBuyhold
Jul 15, 2026Cantor FitzgeraldOverweightOverweighthold
Jun 30, 2026BTIGBuyBuyhold
Jun 29, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 $2 $3 $4 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.58$-1.36$-1.85---
Avg Forecast$-3.30$-1.29$-2.38$-1.48$0.53$1.86
High Forecast$-3.30$-1.26$-1.27$0.70$3.17$1.86
Low Forecast$-3.30$-1.31$-3.49$-3.95$-3.69$1.86
Surprise %-82.42%5.43%-22.27%---

Revenue Forecast

$10M $23M $36M $49M $62M $75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$14.52M$42.50M$70.72M
High Forecast---$14.52M$42.50M$70.72M
Low Forecast---$14.52M$42.50M$70.72M
Surprise %------

Net Income Forecast

$-100M $-70M $-40M $-10M $20M $50M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-8.40M$-15.59M$-13.72M---
Avg Forecast$-47.89M$-18.69M$-34.53M$-15.84M$-8.53M$26.99M
High Forecast$-47.89M$-18.35M$-18.42M$10.16M$46.00M$26.99M
Low Forecast$-47.89M$-19.03M$-50.65M$-57.32M$-53.55M$26.99M
Surprise %-82.45%-16.61%-60.28%---

MNPR Forecast FAQ

Is Monopar Therapeutics stock a buy?

Monopar Therapeutics stock has a consensus rating of Buy, based on 14 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 11 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Monopar Therapeutics is a favorable investment for most analysts.

What is Monopar Therapeutics's price target?

Monopar Therapeutics's price target, set by 14 Wall Street analysts, averages $126 over the next 12 months. The price target range spans from $105 at the low end to $145 at the high end, suggesting a potential 12.12% change from the previous closing price of $112.38.

How does Monopar Therapeutics stock forecast compare to its benchmarks?

Monopar Therapeutics's stock forecast shows a 12.12% upside, underperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Monopar Therapeutics over the past three months?

  • September 2026: 30.77% Strong Buy, 61.54% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 30.77% Strong Buy, 69.23% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Monopar Therapeutics’s EPS forecast?

Monopar Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.48, marking a -20.00% decrease from the reported $-1.85 in 2025. Estimates for the following years are $0.53 in 2027, and $1.86 in 2028.

What is Monopar Therapeutics’s revenue forecast?

Monopar Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $14.52M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $42.5M, and $70.72M for 2028.

What is Monopar Therapeutics’s net income forecast?

Monopar Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-15.836M, representing an 15.45% increase from the reported $-13.717M in 2025. Projections indicate $-8.525M in 2027, and $26.99M in 2028.